The Patterns of Care, Tolerability and Safety in the First Year of a Novel High Field MR-Linac

Otterloo, Sophie R de Mol van; Christodouleas, John P.; Blezer, Erwin L. A.; Cobben, D.; Erickson, Beth; Fuller, C.D.; Hafeez, S.; Kirby, Anna M.; Lalondrelle, Susan; Mook, Stella; Nowee, Marlies E.; Orrling, Kristina M.; Philippens, M.; Sahgal, Arjun; Schultz, C.J.; Tree, A.; Triest, Baukelien van; Tseng, C.L.; Hall, William A.; Verkooijen, H.

doi:10.1016/j.ijrobp.2020.07.2199

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median (IQR) delivered dose to prostate targets was 36 Gray (Gy) (36-60 Gy) with a median number of fractions of 5 (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). The median (IQR) delivered dose to brain targets was 54 Gy (40-60 Gy) with a median number of fractions of 30 (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30).…”

Section: Dose-fractionation Schemesmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance–Guided Radiotherapy

Westerhoff,

Daamen,

Christodouleas

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceIn 2018, the first online adaptive magnetic resonance (MR)-guided radiotherapy (MRgRT) system using a 1.5-T MR–equipped linear accelerator (1.5-T MR-Linac) was clinically introduced. This system enables online adaptive radiotherapy, in which the radiation plan is adapted to size and shape changes of targets at each treatment session based on daily MR-visualized anatomy.ObjectiveTo evaluate safety, tolerability, and technical feasibility of treatment with a 1.5-T MR-Linac, specifically focusing on the subset of patients treated with an online adaptive strategy (ie, the adapt-to-shape [ATS] approach).Design, Setting, and ParticipantsThis cohort study included adults with solid tumors treated with a 1.5-T MR-Linac enrolled in Multi Outcome Evaluation for Radiation Therapy Using the MR-Linac (MOMENTUM), a large prospective international study of MRgRT between February 2019 and October 2021. Included were adults with solid tumors treated with a 1.5-T MR-Linac. Data were collected in Canada, Denmark, The Netherlands, United Kingdom, and the US. Data were analyzed in August 2023.ExposureAll patients underwent MRgRT using a 1.5-T MR-Linac. Radiation prescriptions were consistent with institutional standards of care.Main Outcomes and MeasuresPatterns of care, tolerability, and technical feasibility (ie, treatment completed as planned). Acute high-grade radiotherapy-related toxic effects (ie, grade 3 or higher toxic effects according to Common Terminology Criteria for Adverse Events version 5.0) occurring within the first 3 months after treatment delivery.ResultsIn total, 1793 treatment courses (1772 patients) were included (median patient age, 69 years [range, 22-91 years]; 1384 male [77.2%]). Among 41 different treatment sites, common sites were prostate (745 [41.6%]), metastatic lymph nodes (233 [13.0%]), and brain (189 [10.5%]). ATS was used in 1050 courses (58.6%). MRgRT was completed as planned in 1720 treatment courses (95.9%). Patient withdrawal caused 5 patients (0.3%) to discontinue treatment. The incidence of radiotherapy-related grade 3 toxic effects was 1.4% (95% CI, 0.9%-2.0%) in the entire cohort and 0.4% (95% CI, 0.1%-1.0%) in the subset of patients treated with ATS. There were no radiotherapy-related grade 4 or 5 toxic effects.Conclusions and RelevanceIn this cohort study of patients treated on a 1.5-T MR-Linac, radiotherapy was safe and well tolerated. Online adaptation of the radiation plan at each treatment session to account for anatomic variations was associated with a low risk of acute grade 3 toxic effects.

show abstract

Section: Dose-fractionation Schemesmentioning

confidence: 99%

“…5 Initial patterns of care, tolerability, and safety of the 1.5-T MR-Linac have been reported previously. 6,7 Herein we report updated safety outcomes of the 1.5-T MR-Linac with a focus on patients treated with online adaptation (ie, ATS).…”

Section: Introductionmentioning

confidence: 99%